247 related articles for article (PubMed ID: 18334972)
21. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
[TBL] [Abstract][Full Text] [Related]
22. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
Zhang D; Pal A; Bornmann WG; Yamasaki F; Esteva FJ; Hortobagyi GN; Bartholomeusz C; Ueno NT
Mol Cancer Ther; 2008 Jul; 7(7):1846-50. PubMed ID: 18644997
[TBL] [Abstract][Full Text] [Related]
23. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
24. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
Rusnak DW; Alligood KJ; Mullin RJ; Spehar GM; Arenas-Elliott C; Martin AM; Degenhardt Y; Rudolph SK; Haws TF; Hudson-Curtis BL; Gilmer TM
Cell Prolif; 2007 Aug; 40(4):580-94. PubMed ID: 17635524
[TBL] [Abstract][Full Text] [Related]
25. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Liu Z; Fusi A; Schmittel A; Tinhofer I; Schneider A; Keilholz U
Cancer Biol Ther; 2010 Nov; 10(9):860-4. PubMed ID: 20855957
[TBL] [Abstract][Full Text] [Related]
26. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Singla S; Pippin JA; Drebin JA
Oncol Rep; 2012 Dec; 28(6):2211-6. PubMed ID: 23007710
[TBL] [Abstract][Full Text] [Related]
27. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
[TBL] [Abstract][Full Text] [Related]
28. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
[TBL] [Abstract][Full Text] [Related]
29. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
J Cell Physiol; 2011 Jan; 226(1):52-7. PubMed ID: 20658522
[TBL] [Abstract][Full Text] [Related]
30. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
Montemurro F; Valabrega G; Aglietta M
Expert Opin Biol Ther; 2007 Feb; 7(2):257-68. PubMed ID: 17250463
[TBL] [Abstract][Full Text] [Related]
31. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
[TBL] [Abstract][Full Text] [Related]
32. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
33. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
[TBL] [Abstract][Full Text] [Related]
34. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
[TBL] [Abstract][Full Text] [Related]
35. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F
BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.
Sambade MJ; Camp JT; Kimple RJ; Sartor CI; Shields JM
Radiother Oncol; 2009 Dec; 93(3):639-44. PubMed ID: 19853943
[TBL] [Abstract][Full Text] [Related]
37. Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.
Zhang L; Ngo JA; Wetzel MD; Marchetti D
Neoplasia; 2015 Jan; 17(1):101-13. PubMed ID: 25622903
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
39. Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.
Imami K; Sugiyama N; Imamura H; Wakabayashi M; Tomita M; Taniguchi M; Ueno T; Toi M; Ishihama Y
Mol Cell Proteomics; 2012 Dec; 11(12):1741-57. PubMed ID: 22964224
[TBL] [Abstract][Full Text] [Related]
40. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
